Ralph M. Ellison

RALPH M. ELLISON is Chief Executive Officer and President of DOR
BioPharma Inc. Dr. Ellison was a co-Founder, Director and Chief
Executive Officer of PolaRx Biopharmaceuticals, Inc., an oncology
focused drug development company that developed Trisenox (arsenic
trioxide) for the treatment of cancer. In January 2000, PolaRx was
acquired by Cell Therapeutics, Inc., a public biopharmaceutical company
based in Seattle, Washington. During his tenure as the Chief Executive
Officer of PolaRx, Dr. Ellison was responsible for all aspects of
PolaRx’s drug development program from IND filing through the end of
Phase III testing. He then worked closely with Cell Therapeutics during
the preparation and filing of the new drug application for Trisenox’
which was ultimately approved by the FDA in 2000 for the treatment of
relapsed acute promyelocytic leukemia (APL), a life-threatening cancer
of the blood. Trisenox’ was developed and approved in three years (as
measured by the time from IND filing to NDA approval), making it the
fastest oncology product developed and approved by the FDA. Trisenox’ is
currently in clinical trials to treat more than 10 types of cancer,
including multiple myeloma, myelodysplasia and chronic myeloid leukemia.
Prior to founding PolaRx, Dr. Ellison started and ran a contract
research organization which was a division of RTL, Inc., a
pharmaceutical testing facility based in New York. At RTL he spent five
years designing, implementing and completing clinical trials for both
large and small pharmaceutical companies. Dr. Ellison’s experience
includes the development of anticancer compounds, antifungals,
analgesics, anti-inflammatories, antibiotics and drug delivery systems.
Dr. Ellison holds a degree of Doctor of Medicine from the University of
the Witwatersrand in South Africa and a Master of Business
Administration degree from the University of Cape Town, South Africa.

Related Interviews:

Ralph Ellison - Dor Biopharma Inc (dor)
September 29, 2003